Journal of Biological Chemistry · 2014 · 58 citations · 35 references
PharmacyMedicinal ChemistryMolecular BiologyAntibody EngineeringDrug DesignDrug DiscoveryAntibody CharacterizationAntibody DiscoveryBispecific AntibodiesGlycoengineering Of AntibodiesLigand BindingTherapeutic Antibody DevelopmentBispecific Antibody CombinationsBispecific Antibody ConjugatesBispecific Antibody DiscoveryBispecific Antibody FormatsBispecific Antibody FragmentsEpidermal Growth Factor Receptor InhibitionInsulin-like Growth Factor-1Targeted Kinase Inhibition
In the present study, we have developed a novel one-arm single chain Fab heterodimeric bispecific IgG (OAscFab-IgG) antibody format targeting the insulin-like growth factor receptor type I (IGF-1R) and the epidermal growth factor receptor (EGFR) with one binding site for each target antigen. The bispecific antibody XGFR is based on the "knob-into-hole" technology for heavy chain heterodimerization with one heavy chain consisting of a single chain Fab to prevent wrong pairing of light chains. XGFR was produced with high expression yields and showed simultaneous binding to IGF-1R and EGFR with high affinity. Due to monovalent binding of XGFR to IGF-1R, IGF-1R internalization was strongly reduced compared with the bivalent parental antibody, leading to enhanced Fc-mediated cellular cytotoxicity. To further increase immune effector functions triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted in strong antibody-dependent cell-mediated cytotoxicity activity. XGFR-mediated inhibition of IGF-1R and EGFR phosphorylation as well as A549 tumor cell proliferation was highly effective and was comparable with a combined treatment with EGFR (GA201) and IGF-1R (R1507) antibodies. XGFR also demonstrated potent anti-tumor efficacy in multiple mouse xenograft tumor models with a complete growth inhibition of AsPC1 human pancreatic tumors and improved survival of SCID beige mice carrying A549 human lung tumors compared with treatment with antibodies targeting either IGF-1R or EGFR. In summary, we have applied rational antibody engineering technology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inhibition with antibody-dependent cell-mediated cytotoxicity induction and results in superior molecular properties over two established tetravalent bispecific formats.
35
Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text
Medicine, Hematology, Oncology +16
Arnab Chakravarti, Jay S. Loeffler, Nicholas J. Dyson · PubMed · 2002 · 513 citations
Medicine, Oncology, Pharmacology +17